BJDX vs JAZZ · $5.0M cap vs P/E 1988, rev $2.28B
Bluejay Diagnostics Inc (BJDX) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
Bluejay Diagnostics Inc (BJDX) is a medical devices company listed on US.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
BJDX does not have a complete income-statement cache yet.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
BJDX currently screens at market cap $5.0M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the BJDX and JAZZ stock pages for the full models.
Not investment advice.